Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Blood (2024) 144 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2024-206496

Published: 2024

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Blood (2024) 144 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2024-209232

Published: 2024

Journal Articles

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2024-206912

Published: 2024

Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Blood (2023) 142 (Supplement 1): 1063.

https://doi.org/10.1182/blood-2023-178798

Published: 2023

Journal Articles

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Blood (2023) 142 (Supplement 1): 4784.

https://doi.org/10.1182/blood-2023-188115

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions

Katia Beider, Ilana Kalnitsky, Nira Varda-Bloom, Olga Ostrovsky, Avichai Shimoni, Hila Magen, Arnon Nagler

Blood (2023) 142 (Supplement 1): 875.

https://doi.org/10.1182/blood-2023-180516

Published: 2023

Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2023-173317

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi

Blood (2022) 140 (Supplement 1): 10131–10132.

https://doi.org/10.1182/blood-2022-164722

Published: 2022

Journal Articles

High Implementation Adherence to Lenalidomide in Patients with Multiple Myeloma

Avi Leader, Hila Magen, Irina Amitai, Antoine Pironet, Eric Tousset, Alon Rozental, Sabina De Geest, Iuliana Vaxman, Pia Raanani, Arnon Nagler

Blood (2022) 140 (Supplement 1): 8068–8069.

https://doi.org/10.1182/blood-2022-163818

Published: 2022

Journal Articles

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Yael C Cohen, Mor Zada, Shuang-Yin Wang, Ohad S. Bentur, Evgeni Chubar, Amos Cohen, Noa Lavi, Hila Magen, Moshe Gatt, Miri Zektser, Merav Leiba, Galia Stemer, Tamir Shragai, Irit Avivi, Assaf Weiner, Ido Amit

Blood (2021) 138 (Supplement 1): 2725.

https://doi.org/10.1182/blood-2021-149701

Published: 2021

Journal Articles

Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma

Evgenia Rosenberg, Valeria Voevoda, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Amnon Peled, Arnon Nagler, Katia Beider

Blood (2021) 138 (Supplement 1): 1195.

https://doi.org/10.1182/blood-2021-149372

Published: 2021

Journal Articles

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134935

Published: 2020

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Blood (2019) 134 (Supplement_1): 3152.

https://doi.org/10.1182/blood-2019-123560

Published: 2019

Journal Articles

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Noam Benyamini, MD, Adir S, MD, Moshe E. Gatt, MD, Yael C Cohen, MD, Irit Avivi, MD, Svetlana Trestman, MD, Olga Shvetz, MD, Tamar Tadmor, MD, Najib Dally, MD, Yevgeny Chober, Hila Magen, MD, Chezi Ganzel, MD, Osnat Jarchowcky Dolberg, Celia Suriu, MD, Noa Lavi, MD

Blood (2018) 132 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2018-99-115985

Published: 2018

Journal Articles

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Yael C Cohen, Hila Magen, MD, Noa Lavi, MD, Moshe E. Gatt, MD, Evgeni Chubar, MD, Natalia Kreiniz, Tamar Tadmor, MD, Svetlana Trestman, MD, Roy Vitkon, MD, Ory Rouvio, Olga Shvetz, MD, Adir Shaulov, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2018-99-114217

Published: 2018

Journal Articles

Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs)

Katia Beider, Evgenia Rosenberg, Valeria Voevoda, Hanna Bitner, Yaarit Sirovsky, Hila Magen, MD, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Michael Milyavsky, PhD, Amnon Peled, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 1366.

https://doi.org/10.1182/blood-2018-99-114652

Published: 2018

Journal Articles

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

Timothy Brighton, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, David Ghez, Brendan M. Weiss, MD, Andreas Kirsch, Hila Magen, MD, Mercedes Gironella, Dra., Albert Oriol, MD, Matthew Streetly, BMBS, MRCP, MRCPath, Xiang Qin, Rajesh Bandekar, Peter Hu, Ming Qi, MD PhD, Sepideh Nemat, MD PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 3155.

https://doi.org/10.1182/blood.V130.Suppl_1.3155.3155

Published: 2017

NARROW

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

High Implementation Adherence to Lenalidomide in Patients with Multiple Myeloma

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only